Labcorp completed the acquisition of Personal Genome Diagnostics for $575m.

Labcorp, a global life sciences company, completed the acquisition of Personal Genome Diagnostics, a developer of cancer genome testing products, for $575m. “Labcorp’s leadership and scale in diagnostic testing and drug development, coupled with PGDx’s innovative technology and suite of capabilities, will accelerate access to personalized treatments for cancer patients globally. PGDx’s comprehensive portfolio of next-generation sequencing products will meaningfully add to our breadth of capabilities, in line with our strategic priority to lead in oncology. PGDx’s technology is well positioned in an important segment with strong growth prospects. We look forward to welcoming PGDx’s talented team and working together to bring world-class diagnostics, technology and treatments within reach for all," Adam Schechter, Labcorp Chairman and CEO.